Antiretroviral News and Research

RSS

Vorinostat drives HIV from hiding

The addition of vorinostat to current antiretroviral therapy regimens can potentially help to eradicate hidden pockets of dormant human immunodeficiency virus, according to study results published in Nature.

6 Aug 2012

Mylan receives final FDA approval for generic Amidate ANDA

Mylan Inc. today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Etomidate Injection USP, 2 mg/mL packaged in 40 mg/20 mL single-use vials.

6 Aug 2012

Mylan launches 18 antiretroviral products in India to treat HIV/AIDS

Mylan Inc., one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has commenced commercial operations in India, starting with the launch of a comprehensive portfolio of 18 antiretroviral (ARV) products for the treatment of HIV/AIDS.

6 Aug 2012

Novel integrase inhibitor dolutegravir shows promise for HIV-1 treatment

The once-daily integrase inhibitor dolutegravir has shown promise in a phase III noninferiority study comparing it with twice-daily raltegravir for treatment of HIV-1, indicate study results presented at the 19th International AIDS Conference in Washington DC, USA.

3 Aug 2012

Mylan licenses rights to produce and market generic versions of Gilead HIV/AIDS therapies

Mylan Inc. today announced the establishment of a new agreement between its subsidiary Mylan Laboratories Limited and Gilead Sciences Inc. Under this agreement, Mylan has licensed the rights to produce and market generic versions of Gilead HIV/AIDS therapies containing Emtricitabine, including single and fixed-dose combinations.

3 Aug 2012

ART resistance increasing in sub-Saharan Africa

The prevalence of antiretroviral drug resistance is on the rise in sub-Saharan Africa, an increase driven by resistance to non-nucleoside reverse transcriptase inhibitors in east and southern Africa, research shows.

1 Aug 2012

HIV would 'remain a threat' even if world achieved 'AIDS-free generation' by any definition

Lawrence Altman, former senior medical correspondent for the New York Times, writes in an opinion analysis in the newspaper that while there was much discussion about "ending the AIDS epidemic" and an "AIDS-free generation" at the XIX International AIDS Conference (AIDS 2012) last week in Washington, D.C., "[o]ne obstacle is a failure to clearly define the epidemic or what it means to have an AIDS-free generation."

1 Aug 2012

GlobalPost examines debate surrounding PrEP

GlobalPost's "Global Pulse" blog examines questions surrounding the use of the antiretroviral Truvada for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection among people at high risk, as studies released and panel discussions held last week at the XIX International AIDS Conference (AIDS 2012) "raised concerns about the drug's effect on the future of the AIDS fight."

31 Jul 2012

Limited funding, lack of flexibility forces decisions on how to spend money on disease treatment

Noting "the total clinic-level cost of providing a year's worth of antiretroviral drugs ... ha[s] dropped" in some countries, Charles Kenny, a fellow at the Center for Global Development and the New America Foundation, discusses "disagreement over the effectiveness of the global AIDS response" in this Bloomberg Businessweek opinion piece.

31 Jul 2012

'AIDS-free generation' possible with available tools for prevention, but not without political will

Noting that "the XIX International AIDS Conference [AIDS 2012] has just come to a close amid much talk of the beginning of the end of AIDS, turning the tide on HIV and even a potential cure," Julio Montaner, former president of the International AIDS Society (IAS) and director of the B.C. Centre for Excellence in HIV/AIDS, writes in a Globe and Mail opinion piece, "It is now more certain than ever that we have the tools, medicines and expertise to stop this epidemic."

31 Jul 2012

Hydroxychloroquine fails to modify HIV in patients not taking ART

The use of hydroxychloroquine does not reduce CD8 cell activation in HIV-infected patients not taking antiretroviral therapy, research shows.

30 Jul 2012

XIX International AIDS Conference concludes in Washington, D.C.

"The XIX International AIDS Conference [AIDS 2012] drew to a close Friday without the physical presence of President Obama but with a full cast of other high-profile U.S. politicians who expressed their commitment to ending the disease," CQ HealthBeat reports (Norman, 7/27).

30 Jul 2012

Some AIDS experts view health law coverage expansion with hope

Meanwhile, the Obama administration announced it would add new funds to increase access to HIV/AIDS care, but questions remain about whether it will be enough to address waiting lists for the drug assistance program. Also in the news, reports on treatment developments.

30 Jul 2012

Early ART treatment delays AIDS-related health events in HIV-infected individuals

Further analyses of the landmark NIH-funded treatment-as-prevention study (HPTN 052) have found that providing antiretroviral treatment to HIV-infected individuals earlier, when their immune systems are healthier, delays AIDS-related health events, such as chronic herpes simplex virus and tuberculosis, as well as death. Additionally, researchers found that earlier HIV treatment is also cost-effective because it increases survival, prevents costly opportunistic infections and averts transmission of the virus to uninfected individuals.

30 Jul 2012

Economist articles, blog examine research presented at AIDS 2012 conference

The Economist on Friday published two articles from Saturday's print edition regarding the XIX International AIDS Conference (AIDS 2012). One article states that "few areas of international affairs have seen more recent success than the fight against AIDS," and discusses advancements in HIV treatment research and availability.

28 Jul 2012

Research presented at AIDS 2012 conference renews hope of cure for AIDS

Two studies presented at the XIX International AIDS Conference (AIDS 2012) and one published Wednesday in the British journal Nature "have given researchers renewed hope that a cure for AIDS may be possible," the Washington Post reports.

28 Jul 2012

AIDS 2012 speakers warn vulnerable populations will miss out on HIV prevention advances

"Excitement about turning the tide in the fight against HIV is being tempered by researchers who worry some of the most vulnerable populations will miss out on medical advances," delegates of the XIX International AIDS Conference (AIDS 2012) heard at Thursday's plenary session, VOA News reports.

28 Jul 2012

Mylan receives FDA approval for generic Sporanox ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Itraconazole Capsules, 100 mg.

27 Jul 2012

NPR examines whether goal of treating all HIV-positive people with ARVs is feasible

Noting new guidelines released at the XIX International AIDS Conference (AIDS 2012) in Washington, D.C., this week "call for everybody with HIV to be started on antiretroviral drugs [ARVs] as soon as they test positive for the virus," NPR's "Shots" blog examines "whether the goal is achievable, and who would pay for this enormous expansion in treatment."

27 Jul 2012

TB combination drug: an interview with Mel Spigelman, MD, CEO and President of TB Alliance

TB is a leading global killer. It is the second leading infectious disease in the world, behind HIV. TB is spread through the air, so it can affect anyone, but has its worst impact on impoverished communities and those people with HIV.

27 Jul 2012

Antiretroviral News and Research

Vorinostat drives HIV from hiding

Mylan receives final FDA approval for generic Amidate ANDA

Mylan launches 18 antiretroviral products in India to treat HIV/AIDS

Novel integrase inhibitor dolutegravir shows promise for HIV-1 treatment

Mylan licenses rights to produce and market generic versions of Gilead HIV/AIDS therapies

ART resistance increasing in sub-Saharan Africa

HIV would 'remain a threat' even if world achieved 'AIDS-free generation' by any definition

GlobalPost examines debate surrounding PrEP

Limited funding, lack of flexibility forces decisions on how to spend money on disease treatment

'AIDS-free generation' possible with available tools for prevention, but not without political will

Hydroxychloroquine fails to modify HIV in patients not taking ART

XIX International AIDS Conference concludes in Washington, D.C.

Some AIDS experts view health law coverage expansion with hope

Early ART treatment delays AIDS-related health events in HIV-infected individuals

Economist articles, blog examine research presented at AIDS 2012 conference

Research presented at AIDS 2012 conference renews hope of cure for AIDS

AIDS 2012 speakers warn vulnerable populations will miss out on HIV prevention advances

Mylan receives FDA approval for generic Sporanox ANDA

NPR examines whether goal of treating all HIV-positive people with ARVs is feasible

TB combination drug: an interview with Mel Spigelman, MD, CEO and President of TB Alliance

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News